Loading
The European guideline for anal cancer, covering staging, chemoradiotherapy for localised disease, salvage surgery, and chemotherapy and immunotherapy for cancer that has spread.
Evidence-graded guideline from the European Society for Medical Oncology on anal squamous cell carcinoma: diagnosis with MRI and PET-CT, HIV and HPV testing, radical chemoradiotherapy with fluorouracil (or capecitabine) and mitomycin using intensity-modulated radiotherapy, response assessment at 26 weeks, salvage abdominoperineal resection, and, for metastatic disease, carboplatin plus paclitaxel first line on the InterAACT result with anti-PD-1 antibodies after platinum.
It also addresses local excision for small perianal tumours, treatment in people living with HIV, and surveillance after treatment.
Most decisions on the localised and metastatic anal cancer pages, from the chemoradiotherapy schedule to when to operate and what to give for metastatic disease, follow this guideline or its American counterpart.
Shares Localised anal squamous cell carcinoma (stage I to III), Metastatic and recurrent anal squamous cell carcinoma.
Shares Localised anal squamous cell carcinoma (stage I to III), Metastatic and recurrent anal squamous cell carcinoma.
Shares Localised anal squamous cell carcinoma (stage I to III), Metastatic and recurrent anal squamous cell carcinoma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/